156

Palivizumab 100mg/ml Injections

Prescriber Criteria: Consultant Paediatrician

Inpatient use:

- Reserved for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in infants/children aged **<24 months** with one (or more) of the following, following consultation with the Palivizumab Committee:

    1. Chronic lung disease as per the latest version of the *MDH Guideline for the use of Palivizumab*
    2. Congenital heart disease as per the latest version of the *MDH Guideline for the use of Palivizumab.*
    3. Severe combined immunodeficiency syndrome as per the latest version of the *MDH Guideline for the use of Palivizumab.*
    4. On long term ventilation (LTV) aged under 2 years at the start of the RSV season with or without additional co-pathology (heart disease/pulmonary hypertension, intrinsic lung disease (as reflected by oxygen dependency).
    5. Congenital abnormalities of the lung or neuromuscular disease that compromises handling of respiratory secretions.
    6. Requiring treatment for bronchopulmonary dysplasia within the last 6 months.
    7. In NPICU where the clinical picture warrants it.

- Reserved for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by RSV in all children **(including those over the age of 24 months**) who have primary or secondary immunosuppression or respiratory failure or congenital heart failure after consultation with the Palivizumab Committee.

Duration of approval:
6 months